UBS Maintains Neutral on Edwards Lifesciences, Raises Price Target to $260

UBS maintains Edwards Lifesciences (NYSE:EW) with a Neutral and raises the price target from $255 to $260.

Benzinga · 01/31/2020 13:18

UBS maintains Edwards Lifesciences (NYSE:EW) with a Neutral and raises the price target from $255 to $260.